Home Cart Sign in  
Chemical Structure| 726169-73-9 Chemical Structure| 726169-73-9

Structure of Mocetinostat
CAS No.: 726169-73-9

Chemical Structure| 726169-73-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mocetinostat is an inhibitor of HDAC1 (IC50 = 0.15 μM), HDAC2 (IC50 = 0.29 μM) and HDAC3 (IC50 = 1.66 μM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mocetinostat

CAS No. :726169-73-9
Formula : C23H20N6O
M.W : 396.44
SMILES Code : O=C(NC1=CC=CC=C1N)C2=CC=C(CNC3=NC=CC(C4=CC=CN=C4)=N3)C=C2
MDL No. :MFCD10565970
InChI Key :HRNLUBSXIHFDHP-UHFFFAOYSA-N
Pubchem ID :9865515

Safety of Mocetinostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Mocetinostat

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC3

    HDAC3, IC50:1.66 μM

  • HDAC11

    HDAC11, IC50:0.59 μM

  • HDAC2

    HDAC2, IC50:0.29 μM

  • HDAC1

    HDAC1, IC50:0.15 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Neonatal porcine islets-like clusters (NPICCs) 1 µM 6 days Mocetinostat significantly increased the expression of insulin, recapitulating the effect of butyrate in NPICCs, indicating that it promotes the differentiation of neonatal porcine islets by inhibiting class I HDACs. PMC8621544
human melanoma cell lines 600 nM 48 h Inhibition of HDAC1, HDAC2, and HDAC3 resulted in increased expression of invasiveness genes and decreased expression of melanocyte differentiation genes PMC8379183
CD8+T cells 300 nM 3 days Mocetinostat increased the percentage of IFN-γ+TNF-α+cells and secretion of TNF-α PMC8249424
Schwann cells 0.6 µM 24 h Inhibition of HDAC1/2 activity led to a significant increase in the levels of acetylated eEF1A1 PMC7347577
Oligodendrocytes 0.6 µM 24 h Inhibition of HDAC1/2 activity led to a significant increase in the levels of acetylated eEF1A1 PMC7347577
L3.6 cells 500 nM 24 or 72 h To investigate the effects of Mocetinostat on L3.6 cells, which showed a significant increase in CD24 protein levels. PMC5499659
Panc1 cells 500 nM 24 or 72 h To investigate the effects of Mocetinostat on Panc1 cells, which showed a significant increase in CD24 protein levels. PMC5499659
Med1-MB cells 0.5 μM 72 h Mocetinostat, a selective inhibitor of HDAC1 and HDAC2, drastically reduces SHH-MB growth in mouse models, an effect linked to GLI1 acetylation. PMC10850099
HeLa cells 1 µM 2 h To evaluate the target engagement efficiency of Mocetinostat for HDAC1, HDAC2, and HDAC3, results showed significant binding of Mocetinostat to these HDAC isoforms. PMC4686764
HeLa cells 1 µM 2 h Mocetinostat engaged HDAC1, HDAC2, and HDAC3, but negligible binding was observed for HDAC6, HDAC8, and HDAC10. PMC4686764
H841 cells 1.0 μM 72 h Mocetinostat was capable of reducing Vimentin expression and increasing E-cadherin expression, indicating EMT reversal PMC8143037

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Human melanoma xenograft model Intraperitoneal injection 40 mg/kg Every second day for 2 weeks Inhibition of HDAC1, HDAC2, and HDAC3 resulted in increased expression of invasiveness genes and reduced xenograft tumor growth PMC8379183
Mice sciatic nerve crush model intraperitoneal injection 10 mg/kg once daily for 2 days Inhibition of HDAC1/2 activity led to a significant increase in the levels of acetylated eEF1A1 PMC7347577
Mice H841 human SCLC-I xenograft model Oral gavage 100 mg/kg Daily, ongoing treatment Improved tumor control was observed in the mocetinostat-treated group PMC8143037

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02236195 Urothelial Carcinoma PHASE2 COMPLETED 2025-07-16 University of Alabama, Birming... More >>ham, Alabama, 35294, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|Florida Cancer Specialists, Fort Myers, Florida, 33905, United States|University of Chicago, Chicago, Illinois, 60637, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Washington University, Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Rochester, Rochester, New York, 14627, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States Less <<
NCT02282358 Lymphoma|Relapsed and Refracto... More >>ry|Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Less << PHASE1|PHASE2 TERMINATED 2023-05-26 Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.61mL

2.52mL

1.26mL

25.22mL

5.04mL

2.52mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories